Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;32(5):599-606.
doi: 10.1002/hed.21224.

Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience

Anne M Traynor  1 , Gregory M Richards, Gregory K Hartig, Deepak Khuntia, James F Cleary, Peggy A Wiederholt, Søren M Bentzen, Paul M Harari
Affiliations

Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience

Anne M Traynor et al. Head Neck. 2010 May.

Abstract

Background: We retrospectively examined the treatment efficacy and toxicity profile of intensity-modulated radiotherapy (IMRT) plus concurrent weekly cisplatin chemotherapy in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).

Methods: A total of 57 patients with stage III or IV HNSCC were treated with IMRT and concurrent weekly cisplatin (dosed at 30 mg/m(2)) between November 2001 and May 2007. The median prescription dose to the gross tumor volume was 70 Gy (using 2.0-2.2 Gy daily fractions).

Results: In-field tumor control at 2 years was 89.1%, locoregional control was 85.5%, and overall survival was 86.9%. The median radiation dose delivered was 70 Gy. The mean dose intensity of cisplatin administered was 25.7 mg/m(2)/week.

Conclusion: Comprehensive head and neck IMRT to 70 Gy delivered with weekly cisplatin chemotherapy (30 mg/m(2)) is feasible and generally well tolerated.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan Meier estimate of locoregional control at 2 years, with 95% confidence intervals.
Figure 2
Figure 2
Kaplan Meier estimate of overall survival at 2 years, with 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for Locally Advanced Head – and Neck Cancer. J Clin Oncol. 2007;25:4118–4126. - PubMed
    1. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated Irradiation With or Without Concurrent Chemotherapy For Locally Advanced Head and Neck Cancer. N Engl J Med. 1998;338:1798–1804. - PubMed
    1. Denis F, Garaud P, Bardet E, et al. Final Results of the 94–01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone with Concomitant Radiochemotherapy in Advanced-State Oropharynx Carcinoma. J Clin Oncol. 2004;22:69–76. - PubMed
    1. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial. J Clin Oncol. 2000;18:1458–1464. - PubMed
    1. Adelstein D, Li Y, Adams G, et al. An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients with Unresectable Squamous Cell Head and Neck Cancer. J Clin Oncol. 2003;21:92–98. - PubMed